Francine Gervais
Corporate Officer/Principal bei McGill University
Profil
Francine Gervais is a Professor at McGill University.
She was previously a Vice President-Research & Development at BELLUS Health, Inc. and a SVP & Vice President-Pharmaceutical Development at PainCeptor Pharma Corp.
She holds a doctorate degree from the University of Montréal.
Aktive Positionen von Francine Gervais
Unternehmen | Position | Beginn |
---|---|---|
McGill University | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Francine Gervais
Unternehmen | Position | Ende |
---|---|---|
BELLUS HEALTH | Technik-/Wissenschafts-/F&E-Leiter | - |
PainCeptor Pharma Corp.
PainCeptor Pharma Corp. Pharmaceuticals: MajorHealth Technology PainCeptor Pharma Corp. operates as a biopharmaceutical company which engages in the development of pharmaceuticals for chronic and acute pain. It offers next generation therapeutic drugs for the treatment of chronic and acute pain. The firms products includes NGF/p75-TrkA, ASIC1a and ASIC3. The company was founded by Louis Lamontagne in 2003 and is headquartered in St-Laurent, Canada. | Corporate Officer/Principal | - |
Ausbildung von Francine Gervais
University of Montréal | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
PainCeptor Pharma Corp.
PainCeptor Pharma Corp. Pharmaceuticals: MajorHealth Technology PainCeptor Pharma Corp. operates as a biopharmaceutical company which engages in the development of pharmaceuticals for chronic and acute pain. It offers next generation therapeutic drugs for the treatment of chronic and acute pain. The firms products includes NGF/p75-TrkA, ASIC1a and ASIC3. The company was founded by Louis Lamontagne in 2003 and is headquartered in St-Laurent, Canada. | Health Technology |
BELLUS Health, Inc.
BELLUS Health, Inc. Pharmaceuticals: MajorHealth Technology BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. Its product BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch. The company was founded on June 17, 1993 and is headquartered in Laval, Canada. | Health Technology |